AQST's Anaphylm Odyssey: Aquestive's 2025 Results and the FDA's CRL Roadmap

Lead snapshot: ticker AQST, EPS hints, and the revenue forecast in a regulatory detour

Aquestive Therapeutics, Inc. (AQST) reported results for the fourth quarter and full year 2025 that foreground a regulatory pause rather than a simple earnings beat. While the press release notes that, excluding one-time items, the company met its 2025 revenue guidance and posted a non-GAAP adjusted EBITDA loss, the big news is the FDA's Complete Response Letter (CRL) for Anaphylm—a potential first in the world of oral epinephrine rescue medications. There was no disclosed GAAP EPS figure in the release, and there isn’t a stated EPS consensus to chase, but the narrative centers on the company’s ability to resubmit and move forward, with a planned Type A FDA meeting within 30 days and ongoing efforts to secure regulatory approvals in Canada and the EU in 2026. In other words, the earnings write-up leans toward regulatory milestones rather than a clean EPS surprise.

What happened: the CRL, human factors, and the path forward

The CRL identified deficiencies tied to human factors validation—specifically pouch opening and film placement—and requested a single pharmacokinetics (PK) study to assess the impact of packaging and labeling changes. Importantly, the FDA did not flag chemistry, manufacturing, or controls (CMC) deficiencies, and it did not challenge the clinical results that compared Anaphylm to auto-injectors (such as EpiPen and Auvi-Q) in terms of safety and efficacy. The CRL’s scope is thus focused on packaging usability and related PK data, not on the core science of the drug itself.

Management framed the update with optimism: Anaphylm remains central to the company’s strategy, and a Type A meeting with the FDA is anticipated within about a month. The company also reiterated plans to push regulatory applications for Anaphylm in Canada and the EU in 2026, and to extend a revenue-sharing arrangement with RTW to mid-2027. The press release also highlights that, excluding one-time items, the 2025 revenue and non-GAAP EBITDA guidance were met, underscoring the company’s discipline even as it navigates a regulatory detour.

Implications for Aquestive and its peers

The regulatory setback isn’t a light switch turning off demand; it’s a reminder that the real battleground for a product like Anaphylm sits at the intersection of human factors, packaging, and labeling—areas that can stretch timelines even when the clinical data are solid. From an investor perspective, the key questions hinge on the speed and cost of addressing the human factors validation and the PK study, the likelihood of a successful Type A meeting, and how quickly Canada and the EU can become revenue streams if approvals emerge.

For sector peers, the episode underscores a broader theme: the route to market for non-device, non-traditional delivery systems in the epinephrine space is as much about user interaction and packaging as it is about pharmacology. If Anaphylm can clear the human factors and PK hurdles without derailing a broader clinical program, the potential market advantage for an oral epinephrine product could be meaningful—especially in a landscape still dominated by auto-injectors.

Takeaways for investors and traders

Regulatory cadence matters: The Type A meeting and the PK study become key inflection points. A speedy, well-defined plan could convert a hiccup into progress.
EPS and earnings narrative shifts: The release emphasizes non-GAAP EBITDA and revenue guidance rather than a traditional EPS story, signaling that the stock’s sensitivity may be more about regulatory timing than quarterly earnings surprises.
Revenue forecasts under scrutiny: Canada and EU applications in 2026 could provide optionality if approvals align with expectations; financiers will watch for any delta between guidance and actual execution timeframes.
Balance sheet compass: The target of ending FY2026 with around $70 million in cash and cash equivalents sets a runway constraint and will color discussions about whether the company seeks partnerships or strategic moves to extend capital life.
Industry ripple effects: If Anaphylm advances, competitors and partners may accelerate investments in similar non-invasive delivery approaches, especially where patient convenience and rapid access are critical differentiators.

Endgame thoughts: what this portends for the company and its peers

The path ahead tests management’s ability to translate regulatory patience into commercial momentum. If the FDA accepts a robust human factors validation program and the PK study demonstrates that packaging changes don’t alter performance, a resubmission could unlock a meaningful uplift in the company’s narrative. The addition of Dr. Greenhawt as Chief Medical Officer, highlighted in the release, signals a strategic reinforcement in the science and medical strategy that could help rebuild confidence around Anaphylm’s clinical and regulatory messaging.

In the near term, the market will likely reward clarity on the timeline and cost of addressing the human factors and PK requirements, rather than dramatic shifts in top-line numbers. Beyond Aquestive, the sector peers—companies pursuing oral or non-invasive rescue medications—will be watching how a packaging- and usability-centric CRL is handled. Success or failure here may redefine expectations for the regulatory hurdles facing next-gen epinephrine products, and could influence the funding environment for similar late-stage development programs.

Representative language from the release

“We are well-positioned in 2026 to advance Anaphylm, the first and only oral epinephrine rescue medication, towards approval for patients around the world,” said Daniel Barber, President and Chief Executive Officer of Aquestive. The company notes that Anaphylm is a non-device based epinephrine product candidate and emphasizes its potential to transform the treatment landscape if approvals come through.

Conclusion: a regulatory detour, not a denial of ambition

The FDA’s CRL for Anaphylm frames a regulatory hurdle rather than a verdict on the science. The company’s ability to execute a clean refile—addressing human factors, completing the PK study, and maintaining a clear, cost-conscious plan—will be the differentiator. For investors, the signal isn’t the absence of an EPS surprise this quarter, but the speed and credibility of the remedy. If the Type A meeting confirms a feasible path forward, AQST could pivot from regulatory suspense to a narrative of strategic resilience—one that could resonate not just with AQST holders, but with peers navigating similar paths in the evolving field of non-invasive therapeutic delivery.